The BÜHLMANN fCAL® ELISA (EK-CAL) is the UK market-leading calprotectin ELISA. It provides quantitative in vitro determination of faecal calprotectin in high sample throughput environments.
The kit format is a microtitre plate based assay that can be performed manually or on an automated ELISA system to reduce hands-on time.
CE marked protocols are available for the Dynex DS2 and DSx plus the Grifols Triturus®.
Alpha Laboratories Ltd. supplies the Dynex DS2 for capital purchase or reagent rental.
Two different protocols are available with the fCAL ELISA to cover the ranges required for IBD and IBS differentiation plus the extended range format for use in monitoring patient therapy and mucosal healing. This reduces the need for further dilution and repeated assay.
The ranges are 10-600µg/g or 30-1800µg/g.
A consistent cut-off of 50µg/g is used throughout the Bühlmann Calprotectin range.
Simple extraction procedures for Calprotectin are available using the dedicated CALEX® Cap device or the Schebo or Roche extraction devices.
All reagents, standards and controls are provided in one kit and are ready for use.
There is no requirement for reconstituting any component, apart from the wash buffer.
This minimizes any errors as well as ensuring a long shelf life.
- Easy-to-use ELISA kit (total assay time is 75 minutes)
- All reagents are ready to use*
- Kit includes calibrators and controls
- Analytical Sensitivity: <10µg/g Calprotectin in faecal sample
- Established cut-off of 50µg/g
- Measurable range 30-1800µg/g or 10-600µg/g**
* except wash buffer
** depending on which protocol is used
Faecal calprotectin in patients with suspected colorectal cancer: a diagnostic accuracy study
James Turvill, Assad Aghahoseini, Nala Sivarajasingham, Kazim Abbas, Murtaza Choudhry, Kostantinos Polyzois, Kostantinos Lasithiotakis, Dimitra Volanaki, Baek Kim, Fiona Langlands, Helen Andrew, Jesper Roos, Samantha Mellen, Daniel Turnock and Alison Jones
Emily K. Wright, MD, Michael A. Kamm, MD, PhD, Peter De Cruz, MD, PhD, Amy L. Hamilton, BSc, Kathryn J. Ritchie, BN, Jacqueline I. Keenan, PhD, Steven Leach, PhD, Laura Burgess, MSc, Alan Aitchison, BSc, Alexandra Gorelik, MSc, Danny Liew, MD, PhD, Andrew S. Day, MD, PhD, and Richard B. Gearry, MD, PhD
Inflamm Bowel Dis Volume 22, Number 5, May 2016
“FC appeared to be the optimal marker for identification of endoscopic postoperative recurrence, with high sensitivity and NPV. FC measurement is sufficiently sensitive in the postoperative setting after resection of all macroscopic disease to monitor for CD recurrence